Single-domain antibody directed against complement factor B
Target:
Complement factor B
Target description:
The complement system plays a crucial role in immune defense. It is activated via three pathways: the classical pathway (CP), the lectin pathway (LP), and the alternative pathway (AP), resulting in opsonisation, chemoattraction of immune cells and target cell lysis. Complement factor B (fB, 93 kDa) is involved in the formation of C3 convertase C3bBb. fB binds to deposited C3b where it is recognized by factor D (fD). fD, a serine protase, cleaves factor B into fBa (33 kDa) and fBb (60 kDa), fBa is released and fBb remains bound to C3b, forming the C3 and C5 convertase C3bBb. Fb is also involved in initiation of the alternative pathway, the continuous spontaneous hydrolysis of the thio-ester of native C3, converses C3 into C3b-like C3(H2O). The latter binds fB, which then again can be activated by cleavage through fD, releasing fBa. The formed C3(H2O)Bb is the alternative pathway C3 convertase setting downstream activations in motion.
Source:
Recombinant bivalent single-domain antibody (Lama glama), purified from S. cerevisiae using affinity chromatography. Immunization with and phage-display selection on recombinant protein using total elution.
Product details.
Specificity:
Human factor B, human factor Bb.
Formulation:
0.2 µm filtered solution in PBS. The products are equipped with a C-terminal C-Direct tag with an unpaired cysteine for directional conjugation.
Mol. Weight:
15.1 kDa
Ext. Coeff. (ε):
17545 M-1cm-1
A280 at 1g/L:
1.16
Storage:
Shipped on blue ice. Store at 4˚C or -20˚C (aliquots). Addition of 0.02% sodium azide is optional.
